EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
Trial details
- Registry ID
- NCT07523581
- Drugs studied
- Exaluren
TrialRedline tracks 3 clinical trials sponsored by Eloxx Pharmaceuticals, Inc.: 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and SafetyNCT07523581 | Exaluren | Recruiting | 2027-06-30Estimated |
| A Study of ELX-02 in Patients With Alport SyndromeNCT05448755 | ELX-02 | Completed | 2023-09-11Actual |
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleNCT04126473 | ELX-02, Ivacaftor | Completed | 2022-04-06Actual |
Names as written in the registry records.
NCT07523581 · Eloxx Pharmaceuticals, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT05448755 · Eloxx Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: The incidence and characteristics of adverse events. After: Measure: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily.
Before: Estimated. After: Actual.
Before: 8 participants (planned). After: 3 participants (actual).
Before: Estimated. After: Actual.
Before: 30 May 2023. After: 11 Sep 2023.
Before: Recruiting. After: Completed.